Referring Clinicians
Temporary Trial Recruitment Suspension due to the COVID-19 Pandemic
We are disappointed to announce that we will be temporarily suspending all new recruitment to all trials conducted at the Auckland Cancer Trials Center. We will be concentrating our resources to provide the best possible care to patients who are already enrolled in trials and to contribute to local and national efforts of managing the current pandemic. Thank you for your patience.
Trials Recruiting at ACTC
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| Multiple tumour stream | GILEAD (GS-US-494-5484) | A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects with Advanced Solid Tumors | GS-4224 (small molecule oral PDL1 Inhibitor) | Advanced Solid Organ Malignancy with no further treatment options. TPS/CPS >10% in participants of the Biopsy Substudy | Recruitment Open - Phase 1b Dose Escalation Cohort and Biopsy Substudy Expected to open in 2nd quarter 2020 -Phase 2 Basket Dose Expansion Cohort: CPI Naïve -Melanoma, Renal, Urothelial, Gastric/GOJ, HNSCC,MSI High Cancer, Merkel Cell Carcinoma |
| Melanoma (Advanced/ Metastatic) | MK1308-001 | A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | MK1308 (CTLA4 Inhibitor) +/- Pembrolizumab | Metastatic Melanoma with disease progression after PD1 or PDL1 checkpoint inhibitor therapy Cohort F: MK1308+ pembrolizumab (6 weekly) | Recruiting |
| Upper Gastrointestinal (Advance) , Colorectal (Advance) | CITRON | Reducing Oxaliplatin Neurotoxicity: A Phase IB Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer Patients | mFOLFOX OR CAPOX +/- cimetidine | First 2 cycles mFOLFOX + cimetidine or placebo assessing for acute neuropathy. | Recruiting |
| Colorectal (Metastatic) | Medimmune | A phase 1/2 study of Durvalumab and Monalizumab in Adult Subjects with Select Advance Solid Tumours | Durvalumab (antiPDL1) [D] + Monalizumab (anti CD94/NKG2A) [M] + Cetuximab (EGFR inhibitor) [C] | Cohort C2 : RAS, BRAF wildtype, microsatelite stable, must have been exposed to 5FU/Oxali/Irinotecan/Bevacizumab in 1 or 2 lines of therapy. Randomised to either (D+M+C) or (M+C) | Recruiting |
| Merkel Cell Carcinoma | MK-3475-913 | A phase 1 open label, multi-arm , multicenter study of MK-1308 in combination with pembrolizumab for subjects with advanced solid organ tumours | Pembrolizumab(antiPD1) | Unresectable Stage III and Stage IV Merkel Cell Carcinoma( 1st line) | Recruiting |
| Prostate (mCRPC) | MK-3475-365 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | Pembrolizumab +Olaparib or Pembrolizumab +Abiraterone | Cohort A: (Pembro + Olaparib)- Must have received docetaxel +/- second chemo agent, up to 2 generation hormonal manipulations allowed (e.g. abiraterone, enzalutamide) Cohort D (Pembro + Abiraterone + Pred)- Chemo naïve for mCRPC (docetaxel allowed in mCNPC setting), no prior 2ng generation hormonal manipulation OR progressed on enzalutamide. | Recruiting |
| Melanoma, NSCLC, SCLC | NP40435 | Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumours | PD1/TIM3 bi-specific antibody | -Melanoma: after PD1+/- CTLA4 inhibitor (includes uveal melanoma) -NSCLC: CPI experienced, post platinum, must have received at least 4 months of CPI, PDL1>1% -SCLC: CPI-naive | Recruiting |
| Esophageal and Cervical SCC | BP40234 | An Open Label Phase 2 Study Evaluating the activity of FAP-Interleukin2 Variant and Atezolizumab in advanced Solid Organ Cancer | Atezolizumab + FAP Interleukin2 Variant | Second or subsequent line systemic therapy | Recruiting |
How to Refer
Please email all referrals to CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)
Email us for any other inquiries: infoACTC@adhb.govt.nz
Auckland Cancer Trials Centre
Auckland City Hospital,
2, Park Road, Grafton,
1023, Auckland, New Zealand
Patient Referrals
Please email all referrals to: CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)